Abstract

Whole-genome sequencing (WGS) has rapidly transitioned from specialized research laboratories to the direct-to
consumer (DTC) genetic testing marketplace due to declining costs and advances in high-throughput sequencing 
technologies. While these services expand access to genomic information and offer potential benefits for disease 
prediction, ancestry tracing, and personalized health insights, they also raise significant ethical, legal, and social 
concerns. This paper examines the implications of WGS within DTC contexts, focusing on issues of informed 
consent, privacy and data security, governance and regulatory oversight, accountability of service providers, and 
the broader social consequences of commercialization. It highlights how indefinite data storage, third-party data 
sharing, and risks of re-identification challenge traditional frameworks of confidentiality and consumer protection. 
The analysis further reviews national and international regulatory approaches, emphasizing disparities between 
jurisdictions and the absence of binding global standards. Additionally, the study explores challenges relating to 
public trust, transparency, equity of access, and methodological limitations in research using consumer genomic 
data. The paper concludes that while DTC WGS holds transformative potential for healthcare and research, 
stronger regulatory frameworks, transparent consent processes, and robust privacy safeguards are essential to 
ensure responsible innovation and protect consumer rights.